Comparing IN8bio (NASDAQ:INAB) and Cadrenal Therapeutics (NASDAQ:CVKD)

Cadrenal Therapeutics (NASDAQ:CVKD) and IN8bio (NASDAQ:INAB) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, profitability, dividends, institutional ownership, risk and earnings.

Earnings and Valuation

This table compares Cadrenal Therapeutics and IN8bio”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cadrenal Therapeutics	N/A	N/A	-$10.65 million	($8.01)	-0.89
IN8bio	N/A	N/A	-$30.44 million	($5.45)	-0.36

Cadrenal Therapeutics is trading at a lower price-to-earnings ratio than IN8bio, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Cadrenal Therapeutics has a beta of 1.08, meaning that its share price is 8% more volatile than the S&P 500. Comparatively, IN8bio has a beta of 0.02, meaning that its share price is 98% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations and price targets for Cadrenal Therapeutics and IN8bio, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cadrenal Therapeutics	1	0	1	0	2.00
IN8bio	1	1	1	0	2.00

Cadrenal Therapeutics presently has a consensus target price of $32.00, suggesting a potential upside of 347.87%. IN8bio has a consensus target price of $92.00, suggesting a potential upside of 4,605.88%. Given IN8bio’s higher probable upside, analysts clearly believe IN8bio is more favorable than Cadrenal Therapeutics.

Insider and Institutional Ownership

7.9% of Cadrenal Therapeutics shares are owned by institutional investors. Comparatively, 92.1% of IN8bio shares are owned by institutional investors. 26.1% of Cadrenal Therapeutics shares are owned by insiders. Comparatively, 15.5% of IN8bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Cadrenal Therapeutics and IN8bio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cadrenal Therapeutics	N/A	-279.50%	-204.46%
IN8bio	N/A	-147.21%	-108.63%

Summary

IN8bio beats Cadrenal Therapeutics on 6 of the 9 factors compared between the two stocks.

About Cadrenal Therapeutics

Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.

About IN8bio

IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM. It also develops INB-300, INB-410, and INB-500 that are in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.